NCT06097728 2026-03-04
eVOLVE-Meso
AstraZeneca
Phase 3 Recruiting
Clinical Trials
10 trialsNCT04153565 2025-07-17
MK-3475-A17
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT02899299 2024-05-21
CheckMate743
Bristol-Myers Squibb
Phase 3 Completed
NCT02709512 2023-10-04
ATOMIC
Polaris Group
Phase 2/3 Completed
NCT01655225 2022-04-08
A Study of LY3023414 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02639091 2019-11-07
Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors
Bayer
Phase 1 Completed
NCT01907100 2019-03-18
Nintedanib (BIBF 1120) in Mesothelioma
Boehringer Ingelheim
Phase 2/3 Terminated
NCT01604863 2012-11-01
A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
GlaxoSmithKline
Phase 1 Suspended
NCT00528619 2011-04-08
A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT00040625 2007-03-15
ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.
Eli Lilly and Company
Approved for marketing